P arvoviruses (family Parvoviridae) are small (18-to 26-nm), nonenveloped, icosahedral viruses encapsidating a linear single-stranded DNA genome of approximately 5,000 nucleotides (1). Parvovirus B19, currently designated B19V, is a member of the family Parvoviridae, genus Erythrovirus (2). The B19V viral capsid has an icosahedral structure and is comprised of two proteins, VP1 (84 kDa) and VP2 (58 kDa). VP2 is the major protein (95% of the capsid composition) and contains receptor-and coreceptor-binding domains which together with self-assembly domains lead to the formation of highly stable particles (3). The minor capsid protein, VP1, differs from VP2 only in an N-terminal unique region (VP1u) composed of an additional 227 amino acids and has phospholipase A 2 (PLA 2 ) activity (4). VP1u elicits a dominant immune response (5).
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arvoviruses (family Parvoviridae) are small (18-to 26-nm), nonenveloped, icosahedral viruses encapsidating a linear single-stranded DNA genome of approximately 5,000 nucleotides (1) . Parvovirus B19, currently designated B19V, is a member of the family Parvoviridae, genus Erythrovirus (2) . The B19V viral capsid has an icosahedral structure and is comprised of two proteins, VP1 (84 kDa) and VP2 (58 kDa). VP2 is the major protein (95% of the capsid composition) and contains receptor-and coreceptor-binding domains which together with self-assembly domains lead to the formation of highly stable particles (3) . The minor capsid protein, VP1, differs from VP2 only in an N-terminal unique region (VP1u) composed of an additional 227 amino acids and has phospholipase A 2 (PLA 2 ) activity (4). VP1u elicits a dominant immune response (5) .
B19V infection in many instances is subclinical or presents as the mild and self-limiting fifth disease, or erythema infectiosum, typically manifesting as a "slapped cheeks" rash (6) . Infection by B19V during pregnancy can result in several serious complications in the foetus, such as anemia, nonimmune hydrops, and ultimately intrauterine death (7) . B19V is a potent inhibitor of hematopoiesis because it lytically infects erythroid progenitor cells (8) , and in immunodeficient individuals, chronic B19V infection can result in chronic anemia (9) . In individuals with underlying chronic hemolytic disorders, transient aplastic crisis following B19V infection can be a life-threatening complication (10) . Finally, there is some evidence to suggest that B19V may infect other cell types, suggesting a possible involvement in the pathogenesis of a broad range of medical conditions, including idiopathic arthritis, vasculitis, meningoencephalitis, hepatitis, and myocarditis (11) .
Initially, the laboratory diagnosis of B19V infection was hampered by the lack of a cell culture system to grow the virus, necessitating the use of diagnostic tests lacking in sensitivity (12) . Recently, recombinant DNA technology using prokaryotic (e.g., Escherichia coli) or eukaryotic (e.g., insect cells) expression systems has been applied to produce selected B19V antigens, in particular, VP1 and VP2. Prokaryotically expressed VP1/VP2 antigens undergo denaturation, and the antigen epitopes expressed are linear, whereas eukaryotic expression using baculovirus vectors generates empty capsids that are antigenically analogous to the native virus and include conformational epitopes. Assays using linear and those using conformational B19V VP1/VP2 can produce different results, leading to the general conclusion that conformational epitopes should be used for diagnostic purposes (13) . Such assays need to be designed so that the presentation of conformational epitopes is optimized (14) . Antibodies to linear VP2 epitopes are found mostly during acute infections and early convalescence, whereas those to conformational epitopes persist through life. This phenomenon has further been utilized to develop unique serologic assays named epitope type specificity (ETS) EIAs to differentiate past from recent infection (14, 15) . Another useful approach for such a differentiation is determination of maturing IgG avidity with assays using VP1u as the antigen-this approach has been successfully used to identify recent primary infections (16) .
The development of molecular, nucleic acid-based detection methods (PCR) to detect B19V DNA has supported the diagnosis of B19V infection in immunodeficient patients (17) , and the application of B19V viral load testing (qPCR) has aided in the staging of infection in immunocompetent individuals (18) . Unfortunately, low B19V viral loads may be detected throughout the lifetime of some individuals (19) , and additional testing approaches (for example, using a combination of molecular [qPCR] and serological [EIA] data) may prove useful in differentiating recent from past infection (20) .
The aim of the study reported here, a collaboration between the Haartman Institute, University of Helsinki, Finland (HI), and the Virus Reference Department, Public Health England Microbiology Services, Colindale, England (VRD), was to determine the utility of quantitative, molecular (qPCR) and serological (EIA) methods for distinguishing past from recent B19V infection in immunocompetent individuals.
MATERIALS AND METHODS

Samples.
The serum samples used for this study had been sent to VRD for confirmatory or reference testing of B19V infection or immune status. A panel of 78 sera was selected from the serum archives at VRD to represent past (n ϭ 39) and recent (n ϭ 28) B19V infection. A small number (n ϭ 11) sera were selected which were borderline for B19V IgM or for which the B19V IgM result was considered nonspecific. For the past-infection panel, many of the sera were selected on the basis that they had been tested as paired samples, both of which were B19V IgG positive and for which no significant difference in B19V IgG level was observed. For safety reasons, no samples with B19V viral loads greater than 10 9 IU/ml were included in the study panel. The sera had been stored at Ϫ20°C and were transported to HI on dry ice. No clinical information was supplied to HI, and the selected sera were anonymized for the purposes of this study.
VRD in-house B19V quantitative PCR (VRD B19V qPCR). At VRD, 50 l viral DNA was extracted from 100-l serum/plasma samples using MagNA Pure LC total nucleic acid isolation kits (Roche Diagnostics Ltd., Burgess Hill, West Sussex, United Kingdom) run on a MagNA Pure LC instrument (Roche Diagnostics). Quantitative PCR (qPCR) of extracted DNA was performed using a Lightcycler 2 (Roche Diagnostics). The primers used were E1905 Fwd, NS gene (GenBank accession no. AY386330) nucleotides (nt) 2085 to 2102 (5=-TGC AGA TGC CCT CCA CCC A-3=), and E1987 Rev, NS gene nt 2167 to 2187 (5=-biotin GCT GCT TTC ACT GAG TTC TTC-3=). Oligonucleotides were obtained from Eurofins MWG Operon (Ebersberg, Germany). Amplification reactions were performed by adding 5 l DNA to a 15-l reaction mix in Lightcycler capillaries (Roche Diagnostics). The reaction mix per capillary comprised 4 l nuclease-free water (Severn Biotech Ltd., Kidderminster, United Kingdom), 10 l QuantiTect SYBR green PCR MasterMix (Qiagen, Crawley, United Kingdom), and 0.5 l each of primers E1905Fwd and E1987Rev, both at 20 pmol/l. Included in each assay run were dilutions of B19V plasmid PYT103 at 1,000, 100, and 10 copies/l together with negativecontrol (water) samples and internal quality control samples. The amplification conditions were an initial step of 95°C for 15 min followed by 50 cycles (15 s at 94°C, 20 s at 55°C, 20 s at 72°C, and 5 s at 78°C) and a final step of 15 s at 37°C. On completion of the PCR, the shape of the amplification curves was checked, and melting point analysis was performed. The quantification of positive samples was initially expressed in copies/l (equivalent to IU/l). Conversion to IU/ml was achieved by multiplying the result (in IU/l) by the elution volume (in l) and then dividing by the extracted sample volume (in ml). This equated to a factor of 500 by which the IU/l concentration was multiplied to express the quantitation in IU/ml. Positive and indeterminate samples were kept for confirmation of the reaction product by pyrosequencing, using the E1905Fwd primer (21) at 10 pmol/l. Patients with serum B19V loads of Ͻ10 4 IU/ml were interpreted as having past infections and those with viral loads of Ն10 4 IU/ml were interpreted as having recent infections.
The limit of detection of the qPCR was at least 50 IU/ml (in house data) and assay variability was controlled by incorporation of internal quality controls in each run, plotting Shewhart charts and applying Westgard rules. Assay reproducibility was monitored by periodic testing of the 2nd WHO International Standard for Parvovirus B19 DNA 99/802 (National Institute for Biological Standards and Control, Potters Bar, United Kingdom), which always yielded a result within 0.5 log 10 IU/ml of a target value of 5.0 ϫ 10 5 IU/ml. Detection of IgG (VRD B19V IgG EIA) and IgM (VRD B19V IgM EIA) against recombinant VP2 by commercial enzyme immunoassays. B19V IgG and IgM were detected at VRD using the Biotrin parvovirus B19 IgG (catalog no. V519IG) and IgM (catalog no. V619IM) enzyme immunoassays, respectively (DiaSorin S.p.A., Saluggia, Italy). The assays use purified baculovirus recombinant VP2 protein expressed in insect cells. The manufacturer's instructions were followed.
Parvovirus B19 VP2 IgM EIA (HI B19V VP2 IgM EIA). At HI, B19V IgM antibodies were measured using an in-house IgM capture EIA (22) . Microtiter plate wells (Costar, Corning, NY, USA) were coated with goat anti-human IgM (Cappel/ICN Biomedicals, Costa Mesa, CA, USA). After blocking with 3% bovine serum albumin (BSA), serum samples diluted 1:200 in phosphate-buffered saline-Tween (PBST) were added in duplicate for 1 h at room temperature, and then washed 5 times (automated) with PBST. Biotinylated insect cell-produced B19V VP2 virus-like particles (VLPs) (15) in PBST containing 0.5% BSA were then added at 10 ng per microwell, and the plates were kept without shaking for 45 min at 37°C. The plates were washed as before, 100 l/well horseradish peroxidase-conjugated streptavidin (P0397; Dako, Glostrup, Denmark) was added at 1:12,000 in PBST containing 0.5% bovine serum albumin, and the plates were kept for 45 min at 37°C. After washing, the binding of conjugate was visualized by the addition of o-phenylenediamine dihydrochloride (S2045; Dako) and H 2 O 2 at 100 l/well. Following 15 min incubation at 37°C, the plates were read at 492 nm using a spectrophotometer (Labsystems Multiscan EX; Thermo Fisher, Helsinki, Finland). The cutoff absorbance (based on analysis of 2,289 samples from pregnant women) for a negative result was 0.171 and that for a positive result was 0.22, with absorbances between these values being graded as indeterminate (Table 1) .
Focus parvovirus IgG DxSelect modified IgG avidity EIA (VRD B19V IgG avidity EIA). The Focus parvovirus B19 IgG DxSelect EIA (catalog no. EL0100G; Focus Diagnostics, Cypress, CA, USA) uses recombinant VP1 protein. At VRD, all kit reagents were brought to room temperature, and the antigen-coated microwell strips were soaked with wash buffer (350 l per well) for 5 min. The buffer was aspirated from the strips, and 100 l of test or control samples, diluted in assay buffer 1:100, was added to duplicate wells. The strips were sealed and incubated at 22°C for 50 min, after which they were washed once with 350 l wash buffer and blotted dry. Freshly prepared 6 M urea (catalog no. 20,888-4; SigmaAldrich, Gillingham, United Kingdom) was added (200 l/well) to one set of microwells, and 200 l phosphate-buffered saline (PBS) pH 7.2 (catalog no. 20012-019; Life Technologies, Paisley, United Kingdom) was added to the other set. The strips were sealed, incubated for 10 min at 22°C, and then washed (350 l/well) three times with wash buffer. Conjugate (100 l) was then added to all wells, which were sealed and incubated for 30 min at 22°C. The strips were then washed three times as before, and 3,3=,5,5=-tetramethylbenzidine (TMB) substrate (100 l/well) added to all wells. After 10 min incubation in the dark at 22°C, stop solution (100 l/well) was added to all wells, and the absorbance (450 nm/620 nm) was measured using a dual-wavelength photometer (Labsystems iEMS reader; Thermo Fisher Scientific Inc., Basingstoke, United Kingdom).
For samples with absorbances between 0.2 and 2.2, a relative avidity index (RAI) was determined by calculating the percentage of the ratio of sample absorbance with urea to sample absorbance with PBS and expressing the result as a percentage. RAIs less than 30% were interpreted as low avidity, RAIs between 30% and 40% were considered equivocal, and RAIs greater than 40% were interpreted as high avidity. If a sample gave an absorbance of Ͻ0.2, it was assumed that there was insufficient antibody to determine IgG avidity, and if a sample gave an absorbance of Ͼ2.2, it was retested at a higher dilution until an absorbance was generated in the range of 0.2 to 2.2. High avidity was interpreted as evidence of past infection, and low avidity was interpreted as evidence of recent infection.
The cutoffs were generated by modeling the RAIs from 34 sera from cases of past infection (mean RAI, 52.9%; range, 22.6% to 98.1%) and 36 sera from cases of recent infection (mean RAI, 19.0%; range, 3.4% to 62.7%). The coefficient of variation for the assay was Ͻ10%.
Parvovirus B19 VP1 protein-denaturing IgG avidity EIA (HI B19V IgG avidity EIA). At HI, the avidity of VP1 IgG was measured using a protein-denaturing IgG avidity EIA employing a recombinant protein antigen containing the VP1 unique region together with a short segment (8 amino acids [aa]) of the VP1-VP2 shared sequence. Rather than ␤-galactosidase, as in the original method (16) , the B19V sequence (nt 2444 to 3148 in GenBank ID M13178) was cloned in the expression vector pGEX-4T-1 with glutathione S-transferase (GST) as the fusion part. Protein expression in E. coli (BL21 strain) was induced at an optical density at 600 nm (OD 600 ) with 0.5 mg/ml IPTG for 3 h at 37°C. The fusion protein was purified with glutathione Sepharose 4B according to the manufacturer's (Amersham Biosciences, Sweden) instructions. Microtiter plate wells (Costar) were coated overnight with the fusion protein, unbound antigen was removed by washing, and the plates were dried and stored at Ϫ20°C.
The HI B19V IgG avidity EIA was performed as described previously but with a few minor alterations (16) . In brief, an appropriate number of coated wells was brought to room temperature and then washed three times for 10 min with sample diluent (Ani Labsystems, Vantaa, Finland). Sera for testing were prepared as two dilution series (1 and 2), with 4 dilutions per series per serum sample, in 0.05% PBST and added to designated coated wells. After 60 min incubation at room temperature, dilution series 1 was washed three times for 5 min with 8 M urea in PBST, and dilution series 2 was washed in the same way but with PBST only. Antihuman IgG-horseradish peroxidase conjugate (DakoCytomation) was then added to all wells, which were then incubated for 60 min at room temperature. Following four washes with PBST, binding of antibody was visualized by addition of orthophenylene diamine substrate, and the reaction was stopped by addition of sulfuric acid. The absorbances of each dilution of sample were then measured, and dilution series curves were constructed, enabling comparison of urea treatment to controls (PBST only) using curve-fitting software (23) . Avidity indices were calculated on the basis of the ratio of endpoint titer for urea treatment to that for no urea treatment. The cutoff values for low and high avidity in these assays were 15% and 25%, respectively (Table 1) . High avidity was interpreted as evidence of past infection and low avidity as evidence of recent infection 
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March 2014 Volume 52 Number 3 jcm.asm.org 949 (Table 1 ). The diagnostic performance of the HI B19V IgG avidity EIA was described previously (20) . Parvovirus B19 VP2 IgG epitope type specificity EIA (HI B19V IgG ETS EIA). The HI B19V IgG ETS EIA was performed as previously described (15) . In brief, at HI, the VP2 IgG ETS was measured using as antigens baculovirus-expressed VP2 capsids (33 ng/microwell) and a synthetic monomeric peptide (16 ng/microwell) containing the acute-phaseIgG-specific VP2 epitope KYVTGIN. The ratio of absorbances (492 nm) from these two EIAs (ETS index) was calculated; index values (IVs) of Ͻ10 were considered indicative of recent infection, values of 10 to 20 were treated as borderline, and IVs of Ͼ20 were considered indicative of past infection ( Table 1) .
The diagnostic performance of the HI B19V IgG ETS EIA was described previously (20, 24) .
Statistical methods. Following statistical advice, sensitivity and specificity estimates were not calculated for the EIAs and qPCR due to the highly constructed nature of the serum panel tested. Furthermore, for the purposes of calculation of sensitivity and specificity estimates, a fair comparison of assays is limited because the EIAs have equivocal ranges whereas the qPCR does not (Table 1) . Positive predictive values (PPVs) together with 95% confidence intervals (CIs) were calculated (see Table 3 ) to estimate the correct identification of past versus recent infection, but these values are specific to the panel tested, as they are reliant on prevalence, which, for the purposes of this study, is 28/70 (40%). Indeterminate consensus analysis results were not included in the calculation of PPVs.
RESULTS
Designation of B19V infection status of study panel sera by consensus analysis. Limited clinical information, apart from the reason for testing (Table 2) , was available, and the sera were selected on the basis of testing reports issued by VRD. Sera supplied to HI were anonymized, and no clinical information was given. For comparison of assays, in order to reduce bias, the sera were identified as representing past, recent, or indeterminate infection based on consensus analysis. A consensus interpretation for a sample was applied when at least four out of the six tests applied were similar, for example, past or recent infection, and one test was equivocal or not done. Samples with two or more differing test results were given a consensus interpretation of indeterminate. Consensus interpretations and individual test results, together with clinical details (where available), are shown for each sample in the study panel in Table 2 .
Overall performance of qPCR and EIAs. The consensus analysis (Table 2 ) resulted in a classification of 43 (55.1%) sera as representing past infection and 28 (35.9%) sera as representing recent infection. A total of seven (9.0%) sera were treated as indeterminate ( Table 2 ). The agreement with consensus interpretation for each test is shown in Table 3 . Both VRD B19V qPCR and HI B19V IgM EIA gave the highest agreement with consensus designation for past or recent infection, with an overall agreement of 99% (95% CI, 92 to 100) and positive predictive value (PPV) of 100% (95% CI, 87 to 100). VRD B19V IgM EIA gave the lowest agreement with consensus designation for past or recent infection, with an overall agreement of 87% (95% CI, 77 to 94) and PPV of 76% (95% CI, 59 to 88). For sera designated as representing recent infection by consensus analysis, the VRD B19V IgM EIA gave 100% (95% CI, 88 to 100) agreement.
Performance of VRD B19V qPCR. B19V DNA loads by VRD B19V qPCR ranged from not detected to 9.2 ϫ 10 6 IU/ml. Using the quantitative cutoffs for past and recent infection (Table 1) , there was excellent (99%) overall concordance of classification by VRD B19V qPCR (Table 3) . In relation to specific EIAs, for sera designated as representing recent infection by consensus analysis, there was 96% concordance between recent infection identified by VRD B19V qPCR and that identified by VRD B19V IgM EIA. For sera identified by VRD B19V qPCR as representing past infection, there was 100% concordance (excluding equivocal results) with negative results by VRD B19V IgM EIA and HI B19V VP2 IgM EIA for sera identified as representing past infection by consensus analysis. All of the VRD B19V IgM EIA-positive and HI B19V VP2 IgM EIA-negative sera designated as representing past infection by consensus analysis (Table 4) were identified as representing past infection by VRD B19V qPCR.
In comparison with VRD B19V IgG avidity EIA, identification of recent infection by VRD B19V qPCR showed 96% concordance with sera identified as representing recent infection by consensus analysis ( Table 3) . Identification of past infection by VRD B19V qPCR showed Ͼ95% concordance (excluding equivocal results) with identification of past infection by VRD B19V IgG avidity and HI B19V IgG avidity EIAs for sera identified as representing past infection by consensus analysis. Finally, the HI B19V IgG ETS EIA gave 81% concordance (excluding equivocal results) with identification of recent infection by VRD B19V qPCR and 100% concordance (excluding equivocal results) with identification of past infection by VRD B19V qPCR for sera with a consensus interpretation of past infection and recent infection, respectively ( Table 3) .
Performance of VRD B19V IgM and HI B19V VP2 IgM EIAs. Testing by the VRD B19V IgM EIA yielded 44 sera which were B19V IgM positive, two equivocal results, and 32 B19V IgM-negative sera. At HI, testing of 77/78 sera by the B19V VP2 IgM EIA yielded 26 sera which were B19V IgM positive, two sera which were B19V IgM equivocal, and 49 sera which were B19V IgM negative. The concordance between the VRD B19V IgM EIA and HI B19V VP2 IgM EIAs was as follows (excluding four sera giving equivocal results): 26 sera were IgM positive in both assays, 32 sera were IgM negative in both assays, 15 sera gave discordant results, and one serum was untested. The test profiles of the discordant sera are shown in Table 4 . One B19V IgM-discordant serum (AV43), identified as representing recent infection by consensus analysis, was marginally positive (test-to-cutoff ratio ϭ 1.5) by the VRD B19V IgM EIA and IgM negative by the HI B19V VP2 IgM EIA. The low positive result by the VRD IgM EIA was corroborated by the detection of low-avidity IgG in both the VRD and HI IgG avidity EIAs. Nine sera designated as representing past infection by consensus analysis were IgM positive by the VRD B19V IgM EIA and IgM negative by the HI B19V VP2 IgM EIA. The IgM-negative results by the HI B19V VP2 IgM EIA were supported by the detection of high-avidity B19V IgG in all sera tested by the HI avidity EIA and seven sera tested by the VRD avidity EIA (Table 4) .
There was 100% and 96% concordance (excluding equivocal results) of IgM detection as a marker for recent infection, based on comparison with consensus analysis results for the VRD and HI B19V IgM EIAs, respectively (Table 3 ). For sera identified as representing past infection by consensus analysis, the VRD B19V IgM EIA (excluding equivocal results) gave 77% concordance, whereas the HI B19V VP2 IgM EIA gave 100% concordance (Table 3) .
Performance of B19V IgG avidity assays. The percentage relative avidity indices of the samples tested by the VRD B19V IgG avidity EIA ranged from 3.4 to 98.1 (Fig. 1) . According to the VRD assay interpretative criteria (Table 1) , 37 (48%) sera had IgG of high avidity, 9 (12%) sera tested equivocal, and 31 (40%) sera had IgG of low avidity. In terms of infection status designated by consensus analysis, 34/37 (92%) high-avidity sera were identified as representing past infection and 3/37 (8.1%) were identified as indeterminate infection. A total of 27/28 (96%) sera designated as representing recent infection by consensus analysis were of low avidity (Table 3) . A total of 34/42 (81%) sera designated as representing past infection by consensus analysis were of high avidity ( Table 3) . The relative avidity indices (in percent) of the samples tested by the HI assay ranged from 2.2 to 78 (Fig. 1) . Avidity results were available for 73/78 samples tested at HI, as 5/78 (6%) samples were nonreactive in the corresponding VP1 IgG assay. Using the HI avidity assay interpretative criteria, 50/73 (68%) sera had IgG of high avidity, 10/73 (14%) tested equivocal, and 13/73 (18%) had IgG of low avidity. In terms of infection status by consensus analysis, 39/49 (80%) high-avidity sera were identified as representing past infection, 4/49 (8%) were identified as representing recent infection, and 6/50 (12%) were indeterminate (Table 3) . A total of 13/25 (52%) sera identified as representing recent infection by consensus analysis were of low IgG avidity, and 8/25 (32%) sera were equivocal (Table 3) . A total of 40/43 (93%) sera identified as representing past infection by consensus analysis were of high avidity.
The concordance between the VRD B19V IgG avidity EIA and the HI B19V IgG avidity EIA cannot be determined, as 20 sera gave equivocal results and five sera were not tested in the HI B19V IgG avidity EIA. A total of seven sera (Table 2) gave discordant results: low avidity in the VRD B19V IgG avidity EIA and high avidity in the HI B19V IgG avidity EIA. Three of these sera (AV51, AV72, and AV74) were designated as representing recent infection by consensus analysis, three (AV45, AV56, and AV66) were designated indeterminate, and one serum (AV5) was designated as representing past infection.
The distributions of avidity results obtained with the two EIAs, compared with the consensus interpretative results (recent versus past), are shown in Fig. 1 . While the bimodal distributions of avidities by the two assays were similar and in general corresponded with the assay cutoff criteria, the positions of the assay cutoffs relative to the avidity distributions differed. The HI B19V IgG avidity EIA identified 39/40 (98%) of the past-infection sera tested; however, four (16%) sera with consensus analysis interpretations of recent infection gave high-avidity results (Table 3) . Conversely, the VRD B19V IgG avidity EIA identified 27/28 (96%) of the sera designated as representing recent infection by consensus analysis; however, one serum (2%) designated as representing past infection by consensus analysis was low avidity (Table 3) .
Performance of HI B19V IgG ETS EIA. Results (ETS indices) were available for 75/78 sera tested by the HI B19V IgG ETS EIA, and according to the assay interpretative criteria, 20 (27%) sera were identified as representing recent infection, 48 (64%) sera were identified as representing past infection and seven (9%) sera tested equivocal (Table 3 ). The concordance with a consensus analysis designation of past infection was 40/42 (95%), and the concordance with a consensus analysis designation of recent infection was 18/27 (67%).
There was 100% concordance (excluding equivocal results) of the HI B19V IgG-ETS EIA identification of sera as representing past infection and the determination of high-avidity IgG by the HI B19V IgG avidity EIA. Comparison of the HI B19V IgG-ETS EIA with the VRD B19V IgG avidity EIA identification of sera as rep- resenting past infection gave 97% concordance. The HI IgG-ETS EIA showed less concordance (63%) with the VRD B19V IgG avidity EIA when applied to sera designated as representing recent infection by consensus analysis.
DISCUSSION
Detection of B19V IgG and B19V IgM underpins the diagnosis of B19V infection in immunocompetent individuals. Specific IgG may last for years and is consistent with protection, whereas specific IgM appears early in infection and then rapidly declines, although it can persist for months (13, 20) . The discrimination of recent infection from past infection using B19V IgG and B19V IgM EIAs alone can be subject to error because of discrepant test results. For these reasons, a comparison of different methods for staging B19V infection was undertaken, using sera designated as representing past infection, indeterminate, or representing recent infection following consensus analysis. Consensus analysis was used because there is no recognized gold standard assay for the identification of past or recent B19V infection. A reliable consensus interpretation of past or recent infection is dependent on the assumption that a number of tests are used which have equal abilities to identify infection as past or recent. Such an approach has been used by others (25) in situations where a gold standard assay result is not available. A number of studies have shown that B19V IgG and IgM have different reactivities against conformational and linear epitopes of VP1 and VP2 antigens (13, 14, 24) , and this has led to the development of assays for differentiating past from recent B19V infection (14, 15, 26) . In the study reported here, the performance of an in-house HI B19V VP2 IgM EIA was compared to that of a com- mercial (Biotrin) VRD B19V IgM EIA (Tables 3 and 4) . For many years, VRD has used the (Biotrin) VRD B19V IgM EIA (Table 1) as part of a routine panel of assays for B19V testing, and in our experience, low positive IgM results (test-to-cutoff ratio Ͻ 4) need to be interpreted with caution. In the present study (Table 4) , there were nine discordant sera which tested VRD B19V IgM EIA positive despite having a consensus interpretation of past infection. All nine discordant sera tested B19V IgM negative in the HI B19V VP2 IgM EIA, which identified them as representing past infection.
A useful addition to B19V IgM detection is the determination of B19V IgG avidity. There is extensive evidence that low avidity correlates with recent infection and as the primary antibody response matures the antibody avidity increases (27) . Previously, B19V IgG avidity assays using VP1 antigens have been shown to be suitable for identification of past or recent infections (16, 26) . In the study reported here, a commercial B19V IgG assay (Focus B19 IgG DxSelect), which uses a recombinant VP1 protein, has been converted to a protein-denaturing avidity assay (27) VRD B19V IgG avidity EIA (Table 1) . Based on the results presented in this study (Table 3) , the possibility of a commercial EIA (VRD B19V IgG avidity EIA) which is effective in pinpointing past or recent infection is introduced.
Following the observation that VP2 conformational epitopes were recognized by IgG produced throughout infection whereas VP2 linear epitopes were recognized only during recent infection, a VP2-IgG ETS-EIA was developed and evaluated at HI (14, 15) . The HI B19V IgG ETS-EIA (Table 1) , used in the study reported here, showed high concordance (95%) with consensus identification of past infection but lower concordance (85%) with sera designated as representing recent infection by consensus analysis (Table 3) .
No single EIA gave a 100% identification of past and recent infection as designated by consensus analysis. We concur with Enders et al. (20) , who suggested that supplementary serological assays such as those measuring VP1 IgG avidity or VP2 IgG-ETS be performed to improve the diagnosis of B19V primary infection, as an improved ability to identify when the infection has taken place facilitates patient management. Generally speaking, due to prolonged, recurrent, or false reactivity, reliance on IgM results alone for diagnosis of viral infections should be avoided (24, 28) .
Determination of B19V viral load represents an alternative approach to serology for staging of B19V infection. High viremia levels of B19V are associated with recent infection; however, in immunocompetent individuals, low levels of B19V DNA may persist for months or even years (19) . It is important that the qPCR used be able to detect B19V genotypes 1, 2, and 3 (29) . The primers used for the VRD B19V qPCR have been selected on the basis of conserved regions derived from multiple sequence alignment of the three B19V genotypes (19, 21) . The VRD B19V qPCR has been performed over a number of years to test thousands of samples, and appropriate cutoffs (Table 1) for differentiating past from recent infection have been derived through auditing of clinical and laboratory data. In primary infection, initial viral replication may result in DNA loads as high as 10 14 IU/ml; however, this is transient, and as the immune response is activated and specific antibody is produced, there is a rapid diminution of viral load to a level of 10 2 to 10 3 IU/ml, which may persist for many years (30) . The finding of B19V antibody negativity in sera in which high viral loads have been detected is always possible (31) during the preseroconversion phase; however, VRD rarely receives such sera and would not routinely test for B19V antibody in such cases unless clinically indicated. Consequently, preseroconversion-phase sera were not included in the study panel. An additional confounding factor for B19V qPCR is the potential for the continuing detection of low-level viral loads in an immunocompetent individual over a number of years due to the persistence of B19V in tissues, potentially for life, resulting in the release of B19V DNA into the blood (32) . For these reasons it is not advisable that B19V qPCR, performed alone, be relied upon to differentiate past from recent infection.
A limitation of the study reported here is that an initial bias was introduced through selection of sera at VRD on the basis of testing reports. It would have been desirable to have dated and sequential samples with associated clinical information; however, test request forms usually contained a minimal amount of clinical data ( Table 2 ). At HI, the anonymized sera were tested in the absence of any background information and the results and interpretations were returned to VRD. To avoid bias toward any one particular test, consensus analysis was used to classify samples as indicating past or recent infection or as indeterminate. The designation of sera as indeterminate often leads to a request for samples for further testing together with collection of additional clinical information so that appropriate advice can be given.
To conclude, as shown in Table 3 , both B19V qPCR and B19V EIAs showed high overall agreement with consensus determinations of past or recent infection. Appropriate selection of a combination of tests (e.g., VRD B19V qPCR and VRD B19V IgM EIA) can maximize the likelihood of correct designation of the stage of infection as past or recent. A number of specific findings in the study reported here need to be highlighted; first, the Biotrin IgM EIA (VRD B19V IgM EIA) used at VRD (Table 1) yielded a significant number of clinically inappropriate positive results; however, this finding may be batch related. Second, an in-house B19V IgM EIA, developed at HI (HI B19V VP2 IgM EIA), correctly identified VRD B19V IgM EIA false-positive sera (designated as representing past infection by consensus analysis) (Table 4) . Third, an adaptation of a commercial assay (VRD B19V IgG avidity EIA), performed at VRD, proved useful for the determination of B19V IgG avidity, and the commercial availability of such an assay would be beneficial for the investigation of stage of infection in the absence of other methods. 
